International referral centers and research networks

Team members are strongly involved in national referral centers of rare diseases, including:

• National referral center for toxic bullous diseases and severe skin adverse reactions TOXIBUL (Saskia Oro, leader).
• Competence center for auto-immune bullous dermatoses MALIBUL (Saskia Oro, leader).
• National referral center for Neurofibromatosis CERENEF (Thomas Bettuzzi, scientific committee).

Members are also involved in major international networks:

• European Reference Network for rare skin diseases (ERN-Skin) — Saskia Oro, leader of the toxic bullous dermatoses and severe drug reactions group (ToxiTEN).
• European Academy of Dermatology and Venereology (EADV) – Task force epidemiology — Emilie Sbidian, co-leader.
• Global Atlas on Vitiligo – International League of Dermatological Societies (ILDS) — Khaled Ezzedine (leader and steering committee).
• European Society of Epidemiology in Dermatology (ESDR) — Emilie Sbidian (steering committee), Khaled Ezzedine and Laurence Le Cleach (scientific committee).
• Cochrane Skin Group — Laurence Le Cleach (director), Emilie Sbidian (member).
• CHORD Cochrane Collaboration — Khaled Ezzedine (co-chair of the methods group and steering committee).

Pharmacoepidemiology and clinical translation

Our strong pharmacoepidemiology orientation pushes us to bring our findings as close as possible to clinical use. Our expertise in systematic reviews and meta-analyses enables us to synthesize data on the efficacy and safety of available therapies for a given IMID.

These results have led to the development of collaborations with international guideline groups:

• National — British Academy of Dermatologists (BAD).
• European — EuroGuiDerm.
• Canadian — Canadian Agency for Drugs and Technologies in Health (CADTH).
• United States — American Academy of Dermatology (AAD).

Real-world data and national health databases

We have developed a solid expertise in the use of the French medico-administrative database, allowing access to large populations required to assess the true safety profile of drugs.

This expertise has led us to collaborate with policy stakeholders and to serve as experts within national and European health agencies, including The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency's (EMA) committee and Haute Autorité de Santé (HAS).

Clinical decision tools

Our licensing dedicated to drug-related skin adverse events and imputability led to the creation of a decision-making tool (Décitox), designed to assist non-dermatologist clinicians in their daily practice.